Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical β-lactam antibiotic therapy be improved?

International Journal of Antimicrobial Agents

Volumn 30, Issue 5, 2007, Pages 458-462

  Bhat, Sunil ^a   Fujitani, Shigeki ^a   Potoski, Brian A ^a   Capitano, Blair ^a   Linden, Peter K ^a   Shutt, Kathleen ^a   Paterson, David L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Antimicrobial therapy; Empiric therapy; Intensive Care Unit; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; COHORT ANALYSIS; CROSS RESISTANCE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; VENTILATOR ASSOCIATED PNEUMONIA;

ALGORITHMS; AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; INTENSIVE CARE UNITS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34848908002     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.05.022     Document Type: Article

References (7)

1. Fink M.P., Snydman D.R., Niederman M.S., et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 38 (1994) 547-557
2. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., and Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289 (2003) 885-888
3. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Fourteenth Informational Supplement. Wayne, PA: NCCLS; 2004.
4. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290 (2003) 2588-2598
5. Singh N., Rogers P., Atwood C.W., Wagener M.M., and Yu V.L. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162 (2000) 505-511
6. Bonhoeffer S., Lipsitch M., and Levin B.R. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94 (1997) 12106-12111
7. El Amari E.B., Chamot E., Auckenthaler R., Pechere J.C., and Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 33 (2001) 1859-1864